CRISPR Therapeutics AG - NAMEN AKT (CRSP)

Historical Portfolio Holders from Q1 2016 to Q3 2024

All holders as of June 30, 2024
Q2 2024
Type / Class
Equity / NAMEN AKT
Shares, excl. options Q2 2024
59.5M
Holdings value Q2 2024
$3.21B
Value change Q2 2024
+$82.2M
Grand Portfolio weight change Q2 2024
+0%
Number of holders
433
Number of buys Q2 2024
51
Number of sells Q2 2024
-83
Average buys Q2 2024 %
+0%
Average sells Q2 2024 %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q3 9.49M $446M -$34.8M $46.98 152
2024 Q2 59.5M $3.21B +$82.2M $54.01 440
2024 Q1 56.7M $3.86B +$181M $68.16 469
2023 Q4 55.5M $3.48B +$79.6M $62.60 469
2023 Q3 54.4M $2.47B -$34.7M $45.39 404
2023 Q2 54.7M $3.07B -$80.8M $56.14 413
2023 Q1 56.2M $2.54B +$38.4M $45.23 372
2022 Q4 55.5M $2.25B -$74.8M $40.65 385
2022 Q3 56.7M $3.7B -$80.2M $65.35 412
2022 Q2 55.5M $3.34B +$272M $60.77 408
2022 Q1 49.5M $3.11B +$484M $62.77 417
2021 Q4 42.9M $3.25B +$73.1M $75.78 425
2021 Q3 40.4M $4.52B -$41.1M $111.93 456
2021 Q2 40.5M $6.56B -$153M $161.89 486
2021 Q1 42.6M $5.2B -$577M $121.85 432
2020 Q4 47.2M $7.22B +$35.3M $153.11 399
2020 Q3 47.9M $4B +$724M $83.64 300
2020 Q2 38.3M $2.81B +$281M $73.49 265
2020 Q1 35.5M $1.5B +$152M $42.41 245
2019 Q4 31.5M $1.92B +$255M $60.90 249
2019 Q3 27.5M $1.13B -$8.3M $40.99 178
2019 Q2 27.4M $1.29B +$108M $47.10 181
2019 Q1 26M $929M +$146M $35.72 166
2018 Q4 22.1M $631M -$57.7M $28.57 152
2018 Q3 22.9M $1.01B +$177M $44.35 174
2018 Q2 18.5M $1.09B -$858K $58.76 173
2018 Q1 18.7M $855M +$304M $45.71 132
2017 Q4 12.5M $293M +$61.8M $23.48 83
2017 Q3 10.1M $180M +$6.2M $17.87 62
2017 Q2 9.69M $155M -$3.86M $16.02 36
2017 Q1 9.69M $210M -$3.15M $21.76 34
2016 Q4 9.83M $198M +$198M $20.26 26
2016 Q2 0 $0 -$1K 0
2016 Q1 40 $1K $0 $25.00 1